FDA ap­proves first gener­ics for Take­da’s Vy­vanse as AD­HD drug short­ages per­sist

With key AD­HD med­ica­tions still in short­age, the FDA on Wednes­day ap­proved a gener­ic ver­sion of Take­da’s Vy­vanse, com­ing af­ter the name-brand drug’s patent ex­pired at the end of Au­gust.

Am­neal Phar­ma­ceu­ti­cals re­ceived FDA ap­proval for its gener­ic lis­dex­am­fe­t­a­mine dime­sy­late cap­sules, which are ap­proved to treat AD­HD in pa­tients 6 and old­er as well as mod­er­ate-to-se­vere binge eat­ing dis­or­der in adults. The agency last week start­ed ap­prov­ing gener­ics of Vy­vanse af­ter sev­er­al patents ex­pired on Aug. 24, ac­cord­ing to the Or­ange Book.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER